To order this 320+ page report, which features 150+ figuresand 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Key Market Insights
§ Over 115 companies, across the world, claim to offer avariety of product development, manufacturing and support services, for varioustypes of biologics that are manufactured / expressed in microbial systems
§ Majority of the players have the necessary infrastructure /capability to produce different biologics, primarily proteins, at all scalesusing bacterial / yeast expression vectors
§ The market features the presence of severalwell-established players across the globe; the US, the UK and Germany emergedas current hubs for production of biologics using microbial strains
§ Several service providers, involved in this domain, aresteadily expanding their capabilities in order to enhance their respectiveservice portfolio and maintain a competitive edge in the industry
§ The growth trend of outsourcing microbial manufacturingoperations is evident from the rise in recent partnership activity, as well asexpansion initiatives undertaken by CMOs to meet the growing demand for novelbiologics
§ Big pharma players have also made significant investmentsin this domain through establishment of new facilities, entering into strategiccollaborations and undertaking financial investments
§ Future growth of the market is likely to be driven byincreased adoption of novel biologics that are produced via microbial systems;we expect the service-based revenues to grow at a CAGR of over 8%
§ In the long term, the projected opportunity for contractbiomanufacturing is anticipated to be distributed across contract serviceproviders of different sizes, scales of manufacturing and key geographicalregions
For more information, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Table of Contents
1. PREFACE
1.1. Scopeof the Report
1.2. ResearchMethodology
1.3. Chapter Outlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1 ChapterOverview
3.2. Overviewof Biopharmaceuticals
3.3. ExpressionSystems Used for Biopharmaceutical Production
3.3.1. MicrobialExpression Systems
3.3.1.1. BacterialExpression Systems
3.3.1.2. FungalExpression Systems
3.3.1.3. YeastExpression Systems
3.3.2. Mammalianversus Microbial Expression Systems
3.4. MicrobialManufacturing Process
3.4.1. CellBanking
3.4.2. UpstreamProcessing
3.4.3. Fermentation
3.4.4. DownstreamProcessing
3.5. Overviewof Contract Manufacturing
3.6. Needfor Outsourcing Microbial Biomanufacturing Operations
3.7. CommonlyOutsourced Microbial Biomanufacturing Operations
3.8. Advantagesand Risks Associated with Outsourcing Microbial Biomanufacturing Operations
3.9. KeyConsiderations while Selecting a CMO Partner
3.10. ConcludingRemarks
4. MARKETLANDSCAPE
4.1. ChapterOverview
4.2. MicrobialContract Biomanufacturing Market: Overall Market Landscape
4.2.1. Analysisby Year of Establishment
4.2.2. Analysisby Company Size
4.2.3. Analysisby Location of Headquarters
4.2.4. Analysisby Location of Manufacturing Facility
4.2.5. Analysisby Scale of Operation
4.2.6. Analysisby Type of Biologic
4.2.7. Analysisby Type of Expression System Used
4.2.8. Analysisby Type of Fermenter
4.2.9. Analysisby Type of Service(s) Offered
4.2.10. Analysisby Regulatory Accreditations / Certifications
4.3. RegionalAnalysis
4.3.1. Analysisby North America
4.3.2. Analysisby Europe
4.3.3. Analysisby Asia Pacific
4.3.4. Analysisby Middle East and North Africa
5. COMPANY COMPETITIVENESSANALYSIS
5.1. ChapterOverview
5.2. Assumptionsand Key Parameters
5.3. Methodology
5.4. CompetitivenessAnalysis
5.4.1. CompetitivenessAnalysis: Companies in North America
5.4.2. CompetitivenessAnalysis: Companies in Europe
5.4.3. CompetitivenessAnalysis: Companies in Asia Pacific
6. COMPANYPROFILES
6.1. ChapterOverview
6.2. MicrobialContract Biomanufacturers based in North America
6.2.1. AGCBiologics
6.2.1.1. CompanyOverview
6.2.1.2. ServicePortfolio
6.2.1.3. ManufacturingCapabilities and Facilities
6.2.1.4. RecentDevelopments and Future Outlook
6.2.2. Aldevron
6.2.2.1. CompanyOverview
6.2.2.2. ServicePortfolio
6.2.2.3. ManufacturingCapabilities and Facilities
6.2.2.4. RecentDevelopments and Future Outlook
6.2.3. BioVectra
6.2.3.1. CompanyOverview
6.2.3.2. ServicePortfolio
6.2.3.3. ManufacturingCapabilities and Facilities
6.2.3.4. RecentDevelopments and Future Outlook
6.2.4. OlogyBioservices
6.2.4.1. CompanyOverview
6.2.4.2. ServicePortfolio
6.2.4.3. ManufacturingCapabilities and Facilities
6.2.4.4. RecentDevelopments and Future Outlook
6.3. MicrobialContract Biomanufacturers Based in Europe
6.3.1. Eurogentec
6.3.1.1. CompanyOverview
6.3.1.2. ServicePortfolio
6.3.1.3. ManufacturingCapabilities and Facilities
6.3.1.4. RecentDevelopments and Future Outlook
6.3.2. NorthwayBiotechpharma
6.3.2.1. CompanyOverview
6.3.2.2. ServicePortfolio
6.3.2.3. ManufacturingCapabilities and Facilities
6.3.2.4. RecentDevelopments and Future Outlook
6.3.3. PortonBiopharma
6.3.3.1. CompanyOverview
6.3.3.2. ServicePortfolio
6.3.3.3. ManufacturingCapabilities and Facilities
6.3.3.4. RecentDevelopments and Future Outlook
6.4. MicrobialContract Biomanufacturers Based in Asia Pacific
6.4.1. EirGenix
6.4.1.1. CompanyOverview
6.4.1.2. ServicePortfolio
6.4.1.3. ManufacturingCapabilities and Facilities
6.4.1.4. RecentDevelopments and Future Outlook
6.4.2. Etinpro
6.4.2.1. CompanyOverview
6.4.2.2. ServicePortfolio
6.4.2.3. ManufacturingCapabilities and Facilities
6.4.2.4. RecentDevelopments and Future Outlook
6.4.3. StelisBiopharma
6.4.3.1. CompanyOverview
6.4.3.2. ServicePortfolio
6.4.3.3. ManufacturingCapabilities and Facilities
6.4.3.4. RecentDevelopments and Future Outlook
7. RECENTPARTNERSHIPS
7.1. ChapterOverview
7.2. PartnershipModels
7.3. MicrobialContract Biomanufacturers: Recent Partnerships
7.3.1. Analysisby Year of Partnerships
7.3.2. Analysisby Type of Partnership Model
7.3.3. Analysisby Scale of Operation
7.3.4. Analysisby Type of Biologic
7.3.5. Analysisby Focus Area
7.3.6. Analysisby Target Therapeutic Area
7.3.7. Analysisby Region
7.3.7.1. Country-WiseDistribution
7.3.7.2. Intercontinentaland Intracontinental Agreements
7.3.8. MostActive Players: Analysis by Number of Partnerships
7.4. MicrobialContract Biomanufacturers: Mergers and Acquisitions
7.4.1. Analysisby Year of Merger / Acquisition
7.4.2. Analysisby Type of Acquisition
7.4.3. RegionalAnalysis
7.4.3.1. Continent-wise Distribution
7.4.3.2. Country-wise Distribution
7.4.3.3. Intercontinental and IntracontinentalDeals
7.4.4. MostActive Players: Analysis by Number of Acquisitions
7.4.5. Analysisby Key Value Drivers
7.4.5.1. Analysisby Year of Acquisition and Key Value Drivers
8. RECENTEXPANSIONS
8.1. ChapterOverview
8.2. MicrobialContract Biomanufacturers: Recent Expansions
8.2.1. Analysisby Year of Expansion
8.2.2. Analysisby Type of Expansion
8.2.3. Analysisby Scale of Operation
8.2.4. Analysisby Type of Biologic
8.3. GeographicalAnalysis
8.3.1. Continent-wiseDistribution
9. MICROBIALFERMENTATION TECHNOLOGY PLATFORMS
9.1. ChapterOverview
9.2. TechnologyPlatforms Commonly Used for Microbial Fermentation
9.3. UpcomingPlatforms-General Technologies
10. ATTRACTIVENESSCOMPETITION MATRIX
10.1. ChapterOverview
10.2. ACMatrix: An Overview
10.2.1. StrongBusiness Segment
10.2.2. AverageBusiness Segment
10.2.3. WeakBusiness Segment
10.3. ACMatrix: Analytical Methodology
10.4. ACMatrix: Analyzing the Data for North America
10.5. ACMatrix: Analyzing the Data for Europe
10.6. ACMatrix: Analyzing the Data for Asia Pacific and Middle East
11. MAKE VERSUSBUY DECISION MAKING FRAMEWORK
11.1. ChapterOverview
11.2. Assumptionsand Parameter Definitions
11.2.1. Scenario1
11.2.2. Scenario2
11.2.3. Scenario3
11.2.4. Scenario4
11.3. ConcludingRemarks
12. BIG PHARMAINITITATIVES IN MICROBIAL BIOMANUFACTURING
12.1. ChapterOverview
12.2. Listof Microbial Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
12.2.1. Analysisby Number of Initiatives
12.2.2. Analysisby Year of Initiative
12.2.3. Analysisby Company and Year of Initiative
12.2.4. Analysisby Purpose of Initiative
12.2.5. Analysis by Company and Purpose of Initiative
12.2.6. Analysisby Type of Initiative
12.2.7. Analysisby Scale of Operation
12.2.8. Analysisby Type of Drug Molecule
12.2.9. Analysisby Type of Microbial Expression System Used
12.2.10. Geographical Analysis by Investment Made
12.3. CompetitiveBenchmarking of Big Pharmaceutical Players
12.3.1. BigPharma Summary
13. CASE STUDY:COMPARISON OF SMALL MOLECULE AND LARGE MOLECULEDRUGS / THERAPIES
13.1. ChapterOverview
13.2. SmallMolecule and Large Molecule Drugs / Therapies
13.2.1. Comparisonof Key Characteristics
13.2.2. Comparisonof Microbial Manufacturing Process
13.2.2.1. Microbial Contract Manufacturers ProvidingServices for Small Molecules
13.2.3. Comparisonof Key Manufacturing-related Challenges
14. MARKETSIZING AND OPPORTUNITY ANALYSIS
14.1. ChapterOverview
14.2. KeyAssumptions and Forecast Methodology
14.3. OverallMicrobial Contract Biomanufacturing Market, 2020-2030
14.3.1. MicrobialContract Biomanufacturing Market for APIs, 2020-2030
14.3.2. MicrobialContract Biomanufacturing Market for FDFs, 2020-2030
14.4. Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5. Microbial Contract BiomanufacturingMarket, 2020, 2025 and 2030: Distribution by Type of Microbial ExpressionSystem Used
14.6. Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale ofOperation
14.7. MicrobialContract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of End User
14.8. Microbial ContractBiomanufacturing Market, 2020, 2025, 2030: Distribution by Key GeographicalRegions
14.8.1. Microbial ContractBiomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Proteins
14.8.1.2. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Enzymes
14.8.1.3. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Growth Hormones
14.8.1.4. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Antibody-based Drugs
14.8.1.5. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Biologics
14.8.1.6. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.7. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Commercial Operations
14.8.1.10. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Preclinical / Clinical Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Small Companies
14.8.1.12. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Mid-sized Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Large / Very Large Companies
14.8.2. Microbial Contract Biomanufacturing Market inEurope, 2020-2030
14.8.2.1. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial Contract Biomanufacturing Marketin Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Antibody-based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Mid-sized Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030:Share of Large / Very Large Companies
14.8.3. MicrobialContract Biomanufacturing Market in Asia Pacific, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Marketin Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Marketin Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Antibody- based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Yeast Cell-basedExpression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Large / Very Large Companies
14.8.4. MicrobialContract Biomanufacturing Market in Middle East and North Africa, 2020-2030
14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Proteins
14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Enzymes
14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Growth Hormones
14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Antibody-based Drugs
14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Other Biologics
14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Bacterial Cell-based Expression Systems
14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Commercial Operations
14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Small Companies
14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share ofMid-sized Companies
14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share ofLarge / Very Large Companies
14.8.5. MicrobialContract Biomanufacturing Market in Latin America, 2020-2030
15. IMPACT OF COVID-19 PANDEMIC ON MICROBIALCONTRACT BIOMANUFACTURING MARKET
15.1. ChapterOverview
15.2. CurrentOptions and Recuperative Initiatives of Key Players
15.2.1. KBIBiopharma
15.2.2. Lonza
15.2.3. PortonPharma Solutions
15.2.4. WackerBiotech
15.2.5. WuxiAppTec
15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity
15.4. Recuperative Strategies for CMO Businesses
15.4.1. Strategies for Implementation in the Short / Mid Term
15.4.2. Strategies for Implementation in the Long Term
16. SWOTANALYSIS
16.1. ChapterOverview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparisonof SWOT Factors
17. CONCLUDINGREMARKS
17.1. ChapterOverview
18. INTERVIEWTRANSCRIPTS
18.1. ChapterOverview
18.2. MeteoricBiopharmaceuticals
18.2.1. CompanySnapshot
18.2.2. Interview Transcript:Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)
18.3. ListBiological Laboratories
18.3.1. CompanySnapshot
18.3.2. Interview Transcript:Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)
18.4. OLON
18.4.1. CompanySnapshot
18.4.2. InterviewTranscript: Andrea Conforto, Sales and Marketing-Bioservices Director)
18.5. LuinaBio
18.5.1. CompanySnapshot
18.5.2. InterviewTranscript: Max Rossetto, General Manager-Business Development
18.6. WACKERBiotech
18.6.1. CompanySnapshot
18.6.2. InterviewTranscript: Rob van Dijk, Business Development Manager (Q4 2019)
19. APPENDIX 1:TABULATED DATA
20. APPENDIX 2:LIST OF COMPANIES AND ORGANISTIONS
Contact Details
GauravChaudhary
+1(415) 800 3415
